Werewolf Therapeutics (HOWL) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

HOWL · Stock Price

USD 0.62-0.18 (-22.50%)

Market Cap: $35.5M

Historical price data

Market Cap: $35.5MPipeline: 2 drugsFounded: 2017HQ: Watertown, United States

Sector Ranking#59 in Immunotherapy / Immuno-Oncology

Overview

Werewolf Therapeutics is on a mission to transform cancer treatment by developing safer, more effective immunotherapies. Its core innovation is the PREDATOR™ protein engineering platform, which creates conditionally activated cytokine prodrugs (INDUKINE™ molecules) designed to activate only in the tumor microenvironment. The company has successfully advanced two lead candidates, WTX-124 (IL-2) and WTX-330 (IL-12), into Phase 1/1b clinical trials for advanced solid tumors and has initiated a strategic alternatives process to maximize shareholder value. Werewolf's strategy centers on leveraging its platform to overcome the historical limitations of potent immunomodulators.

Oncology

Technology Platform

PREDATOR™ protein engineering platform for creating conditionally activated cytokine prodrugs (INDUKINE™ molecules) that remain inactive systemically and activate selectively in the tumor microenvironment via protease cleavage.

Pipeline

2

2 drugs in pipeline

Drug	Indication	Stage	Watch
WTX-330	Advanced or Metastatic Solid Tumors	Phase 1/2
WTX-330	Advanced or Metastatic Solid Tumors	Phase 1

Funding History

3

Total raised:$213M

IPO$85MUndisclosedApr 15, 2021

Series B$72MRA Capital ManagementDec 15, 2020

Series A$56MMPM CapitalJan 15, 2019

Opportunities

Werewolf's technology aims to unlock the full therapeutic potential of highly potent but historically toxic cytokines like IL-2 and IL-12, addressing a major unmet need in immuno-oncology.

Success could lead to best-in-class monotherapies or highly effective combination partners for checkpoint inhibitors in large cancer markets.

Risk Factors

The company faces high clinical development risk with its early-stage candidates, financial risk as a pre-revenue entity requiring additional capital, and intense competition from other firms developing engineered cytokines.

The novel conditional activation mechanism, while promising, remains unproven in late-stage trials.

Competitive Landscape

Werewolf competes in a crowded field of companies engineering cytokines for improved safety, including Alkermes, Sanofi/Regeneron, Synthekine, and Xilio Therapeutics. Its key differentiation is the tumor-specific protease-activated prodrug approach, but clinical data on therapeutic window will be the ultimate differentiator.